AGTC and Otonomy Announce Strategic Collaboration to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
Back to JobsInitial focus on GJB2, the most common cause of genetic hearing loss in newborns GAINESVILLE, Fla. and CAMBRIDGE, Mass. and SAN DIEGO , Oct. 01, 2019 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
Apply Now